Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: Presentation and response to treatment

被引：5

作者：

Aversa, S. M. L. ^{[1
]}

Stragliotto, S. ^{[1
]}

Marino, D. ^{[1
]}

Calabrese, F. ^{[3
]}

Rigotti, P. ^{[4
]}

Marchini, F. ^{[4
]}

Gambino, A. ^{[5
]}

Feltrin, G. ^{[5
]}

Boso, C. ^{[2
]}

Canova, F. ^{[1
]}

Solda, C. ^{[1
]}

Mazzarotto, R. ^{[2
]}

Burra, P. ^{[6
]}

机构：

[1] IRCCS, Div Med Oncol, Ist Oncol Veneto, IT-35128 Padua, Italy

[2] IRCCS, Dept Radiotherapy, Ist Oncol Veneto, IT-35128 Padua, Italy

[3] Univ Padua, Dept Med Sci & Special Therapies, Padua, Italy

[4] Univ Padua, Kidney & Pancreas Transplantat Unit, Dept Med & Surg Sci, Padua, Italy

[5] Univ Padua, Dept Cardiothorac Sci, Padua, Italy

[6] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy

来源：

ACTA HAEMATOLOGICA | 2008年 / 120卷 / 01期

关键词：

post-transplant lymphoproliferative disorders; solid organ transplantation; weekly chemotherapy;

D O I：

10.1159/000155234

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Post-transplant lymphoproliferative disorders (PTLD) is a serious complication after solid organ transplantation. Reduction of immunosuppression (RI) alone is not able to control the disease. We report a prospective analysis of 30 patients with PTLD after heart or kidney transplantation. Only 5 of 30 patients, treated solely with RI, obtained a complete response. Five patients were treated heterogeneously; in the remaining 20, the efficacy and safety of a weekly anthracycline-based chemotherapy were assessed. Sixteen patients obtained a complete remission. One death was related to treatment. With a median follow-up of 36 months, 3-year overall survival was 63.3% and 57% for the entire group and the chemotherapy-treated group, respectively. Moreover, 4 second neoplasms were observed in the chemotherapeutic group. In this study, we demonstrated that most PTLD need other treatment than RI and a weekly regimen is manageable and has a favourable impact on long-term survival. Copyright (C) 2008 S. Karger AG, Basel.

引用

页码：36 / 46

页数：11

共 50 条

[1]

[Anonymous], 2001, Pathology and Genetics

[2]

ARMITAGE JM, 1991, J HEART LUNG TRANSPL, V10, P877

[3] ADVANTAGES OF DETECTING MONOCLONAL-ANTIBODY BINDING TO TISSUE-SECTIONS WITH BIOTIN AND AVIDIN REAGENTS IN COPLIN JARS [J].

BINDL, JM ;

WARNKE, RA .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1986, 85 (04) :490-493

[4]

BIRKELAND SA, 1983, SURGERY, V93, P504

[5] The management of lymphoma in the immunosuppressed patient [J].

Bower, M .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (03) :517-532

[6] Treatment and outcomes of post-transplant lymphoproliferative disease: A single institution study [J].

Buadi, Francis K. ;

Heyman, Meyer R. ;

Gocke, Christopher D. ;

Rapoport, Aaron P. ;

Hakimian, Roger ;

Bartlett, Stephen T. ;

Sarkodee-Adoo, Clarence .

AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (03) :208-214

[7] Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? [J].

Burra, Patrizia ;

Buda, Andrea ;

Livic, Ugolino ;

Rigotti, Paolo ;

Zanus, Giacomo ;

Calabrese, Fiorella ;

Caforio, Alida ;

Menin, Chiara ;

Canova, Daniele ;

Farinati, Fabio ;

Aversa, Savina Maria Luciana .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2006, 18 (10) :1065-1070

[8] BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome [J].

Cesarman, E ;

Chadburn, A ;

Liu, YF ;

Migliazza, A ;

Dalla-Favera, R ;

Knowles, DM .

BLOOD, 1998, 92 (07) :2294-2302

[9] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[10] Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study [J].

Choquet, S ;

Leblond, V ;

Herbrecht, R ;

Socié, G ;

Stoppa, AM ;

Vandenberghe, P ;

Fischer, A ;

Morschhauser, F ;

Salles, G ;

Feremans, W ;

Vilmer, E ;

Peraldi, MN ;

Lang, P ;

Lebranchu, Y ;

Oksenhendler, E ;

Garnier, JL ;

Lamy, T ;

Jaccard, A ;

Ferrant, A ;

Offner, F ;

Hermine, O ;

Moreau, A ;

Fafi-Kremer, S ;

Morand, P ;

Chatenoud, L ;

Berriot-Varoqueaux, N ;

Bergougnoux, L ;

Milpied, N .

BLOOD, 2006, 107 (08) :3053-3057

← 1 2 3 4 5 →